Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Randomized Trial of Carotid Artery Stenting With Balloon Guide Catheter

25. Juni 2026 aktualisiert von: GuoQiang Xu, Hebei General Hospital

Balloon Guide Catheter-Assisted Carotid Artery Stenting With Multimodal Cerebral Protection: A Prospective, Multicenter, Randomized Controlled Trial

This prospective, multicenter, randomized controlled study enrolled patients undergoing carotid artery stenting (CAS) with cerebral embolic protection for carotid artery stenosis. They were randomly assigned to either a combination of proximal balloon occlusion, filter protection, intermediate catheter or filter protection alone. The study included 132 patients, and the primary endpoint was the number of new infarcts on cerebral diffusion-weighted imaging (DWI) within 48 hours (±24 hours) post-procedure.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Carotid artery stenting (CAS) is an established treatment for carotid stenosis, yet the optimal cerebral embolic protection strategy remains uncertain. This prospective, multicenter, randomized, open-label, controlled trial will enroll 132 patients with symptomatic (≥50%) or asymptomatic (≥70%) carotid stenosis, who will be randomly assigned 1:1 to either experimental multimodal protection (Balloon Guide Catheter plus distal filter and intermediate catheter aspiration) or conventional distal filter protection alone. The primary endpoint is the number of new infarcts on post-procedural diffusion-weighted imaging (DWI) assessed within 48 hours (±24 hours), with secondary endpoints including device success and defect rates, incidences of symptomatic and all intracranial hemorrhage within 48 hours post-procedure, ipsilateral target-vessel stroke, TIA, major adverse events (stroke/death/MI), and adverse/serious adverse events at 30 and 90 days, all-cause mortality at 90 days, changes in mRS score at 30 and 90 days, and procedure-related complications (e.g., dissection, hyperperfusion syndrome).

Studientyp

Interventionell

Einschreibung (Geschätzt)

132

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Aged between 18 and 80 years (inclusive), with no gender restriction.
  2. Imaging diagnosis indicates symptomatic carotid artery stenosis (by NASCET method) ≥50% or asymptomatic carotid artery stenosis (by NASCET method) ≥70%.
  3. Suitable for carotid artery stenting.
  4. Good compliance, voluntarily signed the informed consent form, and able to follow up as required.

Exclusion Criteria:

  1. Severe tortuosity or calcification of the diseased vessel, preventing device delivery.
  2. Patients with ipsilateral external carotid artery occlusion or severe stenosis of the intracranial segment of the internal carotid artery.
  3. Patients with contralateral common carotid artery occlusion or severe stenosis or occlusion of the internal carotid artery.
  4. Patients with severe stenosis or occlusion of the vertebrobasilar artery (excluding non-dominant vertebral artery).
  5. Spontaneous intracranial hemorrhage, massive cerebral infarction, progressive stroke, or myocardial infarction within the past 3 months.
  6. Presence of substantial acute or subacute thrombus adjacent to the lesion.
  7. mRS > 3.
  8. Patients with a clear risk of cardioembolism, such as atrial fibrillation, or those with definite indications for anticoagulation.
  9. Chronic obstructive pulmonary disease requiring long-term continuous oxygen therapy.
  10. Patients with prior stent treatment in the ipsilateral head and neck vessels.
  11. Patients with end-stage renal failure requiring dialysis.
  12. Life expectancy less than 6 months.
  13. Patients unsuitable for magnetic resonance imaging (MRI) for any reason.
  14. Patients with absolute or relative contraindications to antiplatelet therapy.
  15. Inability to cooperate with the study due to dementia or mental disorder.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Combined Cerebral Protection (BGC + Filter + intermediate catheter)
Participants in this arm will undergo carotid artery stenting (CAS) with a multimodal cerebral embolic protection strategy, incorporating proximal balloon occlusion via a Balloon Guide Catheter (BGC), distal filter protection, and active aspiration through an intermediate catheter.
Gerät: Balloon Guide Catheter
Balloon guide catheter for proximal flow arrest and debris aspiration during carotid stenting.
Aktiver Komparator: Standard Protection Group (Filter Alone)
Participants in this arm will undergo carotid artery stenting (CAS) with distal filter protection.
Gerät: Filter
Distal embolic filter deployed beyond the stenosis to capture debris during stent placement.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of new infarcts on cerebral diffusion-weighted imaging (DWI) within 48 hours (±24 hours) post-procedure
Zeitfenster: within 48 hours (±24 hours) post-procedure
Total number of new DWI positive lesions on post procedural brain MRI within 48 hours (±24 hours). New lesions are defined as foci of hyperintensity not seen on baseline DWI (if available), or otherwise as lesions consistent with acute embolic infarction.
within 48 hours (±24 hours) post-procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Device Success Rate
Zeitfenster: during the procedure
Device success for the balloon dilation catheter is defined as successful delivery, complete inflation, and smooth retrieval of the catheter system.
during the procedure
Incidence of Major Adverse Events (MAE) within 30 days, including any stroke, death, and myocardial infarction.
Zeitfenster: within 30-day post-procedure
The rate of major adverse events (MAE), defined as the cumulative incidence of any death, stroke, or myocardial infarction within 30-day post-procedure.
within 30-day post-procedure
Changes in mRS score at 30 days and 90 days post-procedure.
Zeitfenster: 30 days and 90 days post-procedure
Modified rankin score measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The range is 0-6 (0 is highest function with no symptoms and 6 is death).
30 days and 90 days post-procedure
Incidence of ipsilateral target vessel stroke at 30 days and 90 days post-procedure.
Zeitfenster: 30 days and 90 days post-procedure
Stroke is defined as an acute neurological deficit of vascular origin lasting ≥24 hours, or lasting <24 hours with neuroimaging evidence of new infarction, occurring in the territory of the treated carotid artery.
30 days and 90 days post-procedure
Incidence of transient ischemic attacks (TIA) at 30 days and 90 days post-procedure.
Zeitfenster: 30 days and 90 days post-procedure
Transient ischemic attacks (TIA) was defined as transient focal neurological deficit of vascular origin lasting <24 hours with no acute infarct on neuroimaging.
30 days and 90 days post-procedure
Incidence of Procedure-related complications (e.g., vessel dissection, hyperperfusion syndrome, etc.).
Zeitfenster: during the procedure
Procedure related complications include vessel dissection, hyperperfusion syndrome, access site events, and other adverse events directly attributable to carotid artery stenting (CAS).
during the procedure
Incidence of adverse events and serious adverse events at 30 days and 90 days post-procedure.
Zeitfenster: 30 days and 90 days post-procedure
The Incidence of Adverse events or severe adverse event at 30 days and 90 days post-procedure.
30 days and 90 days post-procedure
Incidence of symptomatic intracranial hemorrhage within 48 hours (±24 hours) post-procedure.
Zeitfenster: within 48 hours (±24 hours) post-procedure
Symptomatic intracranial hemorrhage defined as any intracranial hemorrhage on imaging with new neurological symptoms or NIHSS increase ≥4, or death.
within 48 hours (±24 hours) post-procedure
Incidence of intracranial hemorrhage within 48 hours (±24 hours) post-procedure.
Zeitfenster: within 48 hours (±24 hours) post-procedure
Incidence of all intracranial hemorrhage on post-procedural brain imaging within 48 hours.
within 48 hours (±24 hours) post-procedure
Incidence of all-cause mortality within 90 days post-procedure.
Zeitfenster: 90 days post-procedure
Incidence of death from any cause occurring within 90 days following the procedure.
90 days post-procedure
Incidence of device defects.
Zeitfenster: during the procedure
The Incidence of device defects in the process of testing, such as label errors, quality problems, malfunctions, etc.
during the procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Hebei General Hospital

Ermittler

  • Hauptermittler: Guodong Xu, Hebei General Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2026

Studienabschluss (Geschätzt)

30. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

25. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. Juni 2026

Zuerst gepostet (Tatsächlich)

1. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

1. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • BGC-2026-01

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren